{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:53:08Z","timestamp":1790754788076,"version":"4.1.0"},"reference-count":126,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,16]],"date-time":"2018-04-16T00:00:00Z","timestamp":1523836800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Innovative Medicines Initiative Joint Undertaking","award":["115369"],"award-info":[{"award-number":["115369"]}]},{"DOI":"10.13039\/501100003130","name":"FWO","doi-asserted-by":"publisher","award":["G.0769.14N"],"award-info":[{"award-number":["G.0769.14N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.ejps.2018.04.016","type":"journal-article","created":{"date-parts":[[2018,4,14]],"date-time":"2018-04-14T00:59:20Z","timestamp":1523667560000},"page":"219-233","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":192,"special_numbering":"C","title":["Drug permeability profiling using cell-free permeation tools: Overview and applications"],"prefix":"10.1016","volume":"119","author":[{"given":"Philippe","family":"Berben","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Bauer-Brandl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Brandl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Faller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00f8ril Eide","family":"Flaten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Christin","family":"Jacobsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Brouwers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Augustijns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2018.04.016_bb0005","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1002\/jps.2600831103","article-title":"Quantitative approaches to delineate paracellular diffusion in cultured epithelial cell monolayers","volume":"83","author":"Adson","year":"1994","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2018.04.016_bb0010","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1023\/A:1018903931777","article-title":"Selective paracellular permeability in two models of intestinal absorption: cultured monolayers of human intestinal epithelial cells and rat intestinal segments","volume":"10","author":"Artursson","year":"1993","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2018.04.016_bb0015","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1517\/17425255.1.2.325","article-title":"The rise of PAMPA","volume":"1","author":"Avdeef","year":"2005","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.ejps.2018.04.016_bb0020","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0928-0987(01)00191-9","article-title":"Drug absorption in vitro model: filter-immobilized artificial membranes: 2. Studies of the permeability properties of lactones in Piper methysticum Forst","volume":"14","author":"Avdeef","year":"2001","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2018.04.016_bb0025","first-page":"365","article-title":"PAMPA\u2013a drug absorption in vitro model 11. Matching the in vivo unstirred water layer thickness by individual-well stirring in microtitre plates","volume":"22","author":"Avdeef","year":"2004","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2018.04.016_bb0030","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ejps.2007.09.009","article-title":"Absorption-excipient-pH classification gradient maps: sparingly soluble drugs and the pH partition hypothesis","volume":"33","author":"Avdeef","year":"2008","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2018.04.016_bb0035","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1023\/A:1010974909998","article-title":"Transport of lipophilic drug molecules in a new mucus-secreting cell culture model based on HT29-MTX cells","volume":"18","author":"Behrens","year":"2001","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2018.04.016_bb0040","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1002\/jps.24496","article-title":"Head-to-head comparison of different solubility-enabling formulations of etoposide and their consequent solubility-permeability interplay","volume":"104","author":"Beig","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2018.04.016_bb0045","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1208\/s12248-017-0052-1","article-title":"Advantageous solubility-permeability interplay when using amorphous solid dispersion (ASD) formulation for the BCS class IV P-gp substrate rifaximin: simultaneous increase of both the solubility and the permeability","volume":"19","author":"Beig","year":"2017","journal-title":"AAPS J."},{"key":"10.1016\/j.ejps.2018.04.016_bb0050","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ejpb.2017.09.012","article-title":"Concomitant solubility-permeability increase: vitamin E TPGS vs. amorphous solid dispersion as oral delivery systems for etoposide","volume":"121","author":"Beig","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2018.04.016_bb0055","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1007\/s11095-006-9137-8","article-title":"PAMPA - excipient classification gradient map","volume":"23","author":"Bendels","year":"2006","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2018.04.016_bb0060","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.xphs.2017.08.002","article-title":"Assessment of passive intestinal permeability using an artificial membrane insert system","volume":"107","author":"Berben","year":"2018","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2018.04.016_bb0065","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ijpharm.2017.12.025","article-title":"The artificial membrane insert system as predictive tool for formulation performance evaluation","volume":"537","author":"Berben","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2018.04.016_bb0070","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ijpharm.2017.04.057","article-title":"Gastrointestinal behavior of itraconazole in humans - part 2: the effect of intraluminal dilution on the performance of a cyclodextrin-based solution","volume":"526","author":"Berben","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2018.04.016_bb0075","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ejps.2003.10.009","article-title":"PAMPA\u2014a drug absorption in vitro model: 7. Comparing rat in situ, Caco-2, and PAMPA permeability of fluoroquinolones","volume":"21","author":"Bermejo","year":"2004","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2018.04.016_bb0080","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ijpharm.2015.07.028","article-title":"Permeapad\u2122 for investigation of passive drug permeability: the effect of surfactants, co-solvents and simulated intestinal fluids (FaSSIF and FeSSIF)","volume":"493","author":"Bibi","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2018.04.016_bb0085","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.ejps.2016.08.041","article-title":"Use of Permeapad\u00ae for prediction of buccal absorption: a comparison to in vitro, ex vivo and in vivo method","volume":"93","author":"Bibi","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2018.04.016_bb0090","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.ejpb.2017.05.001","article-title":"Simultaneous lipolysis\/permeation in vitro model, for the estimation of bioavailability of lipid based drug delivery systems","volume":"117","author":"Bibi","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2018.04.016_bb0095","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S1056-8719(00)00113-1","article-title":"Current methodologies used for evaluation of intestinal permeability and absorption","volume":"44","author":"Balimane","year":"2000","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.ejps.2018.04.016_bb0100","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1023\/B:PHAM.0000022404.70478.4b","article-title":"A dynamic artificial gastrointestinal system for studying the behavior of orally administered drug dosage forms under various physiological conditions","volume":"21","author":"Blanquet","year":"2004","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2018.04.016_bb0105","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/bcpt.12342","article-title":"Mucus as a barrier to drug delivery \u2013 understanding and mimicking the barrier properties","volume":"116","author":"Boegh","year":"2015","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.ejps.2018.04.016_bb0110","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2174\/1568026013394886","article-title":"Strategies for absorption screening in drug discovery and development","volume":"1","author":"Bohets","year":"2001","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejps.2018.04.016_bb0115","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S1387-2656(01)07033-8","article-title":"Liposomes as drug carriers: a technological approach","volume":"7","author":"Brandl","year":"2001","journal-title":"Biotechnol. Annu. Rev."},{"key":"10.1016\/j.ejps.2018.04.016_bb0120","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ejps.2011.12.007","article-title":"In vitro models to evaluate the permeability of poorly soluble drug entities: challenges and perspectives","volume":"45","author":"Buckley","year":"2012","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2018.04.016_bb0125","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejps.2013.04.002","article-title":"Biopharmaceutical classification of poorly soluble drugs with respect to \u201cenabling formulations\u201d","volume":"50","author":"Buckley","year":"2013","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2018.04.016_bb0130","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ejps.2015.03.019","article-title":"New biomimetic barrier Permeapad\u2122 for efficient investigation of passive permeability of drugs","volume":"73","author":"di Cagno","year":"2015","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2018.04.016_bb0135","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0031-6865(96)00031-3","article-title":"Review of theoretical passive drug absorption models: historical background, recent developments and limitations","volume":"71","author":"Camenisch","year":"1996","journal-title":"Pharm. Acta Helv."},{"key":"10.1016\/j.ejps.2018.04.016_bb0140","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S0928-0987(97)10019-7","article-title":"Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs' lipophilicity and molecular weight","volume":"6","author":"Camenisch","year":"1998","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2018.04.016_bb0145","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ejps.2003.07.003","article-title":"The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability","volume":"21","author":"Chan","year":"2004","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2018.04.016_bb0150","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1007\/s11095-007-9517-8","article-title":"A novel design of artificial membrane for improving the PAMPA model","volume":"25","author":"Chen","year":"2008","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2018.04.016_bb0165","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ijpharm.2012.03.050","article-title":"A biorelevant in vitro release\/permeation system for oral transmucosal dosage forms","volume":"430","author":"Delvadia","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2018.04.016_bb0155","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/10837450701702438","article-title":"Formulation, characterization, and in vitro evaluation of bioadhesive gels containing 5-fluorouracil","volume":"13","author":"Dhiman","year":"2008","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.ejps.2018.04.016_bb0160","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0223-5234(03)00012-6","article-title":"High throughput artificial membrane permeability assay for blood\u2013brain barrier","volume":"38","author":"Di","year":"2003","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejps.2018.04.016_bb0170","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4161\/19420862.2015.989042","article-title":"The therapeutic monoclonal antibody market","volume":"7","author":"Ecker","year":"2014","journal-title":"MAbs"},{"key":"10.1016\/j.ejps.2018.04.016_bb0175","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/jps.23509","article-title":"New applications of phospholipid vesicle-based permeation assay: permeation model mimicking skin barrier","volume":"102","author":"Engesland","year":"2013","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2018.04.016_bb0180","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1002\/jps.24315","article-title":"Phospholipid vesicle-based permeation assay and EpiSkin\u00ae in assessment of drug therapies destined for skin administration","volume":"104","author":"Engesland","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2018.04.016_bb0185","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.3109\/03639045.2016.1171334","article-title":"In vitro models to estimate drug penetration through the compromised stratum corneum barrier","volume":"42","author":"Engesland","year":"2016","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejps.2018.04.016_bb0190","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.addr.2011.12.009","article-title":"Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers","volume":"64","author":"Ensign","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejps.2018.04.016_bb0195","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ijpharm.2017.12.038","article-title":"Mucus-PVPA (mucus phospholipid vesicle-based permeation assay): an artificial permeability tool for drug screening and formulation development","volume":"537","author":"Falavigna","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2018.04.016_bb0255","doi-asserted-by":"crossref","first-page":"886","DOI":"10.2174\/138920008786485227","article-title":"Artificial membrane assays to assess permeability","volume":"9","author":"Faller","year":"2008","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.ejps.2018.04.016_bb0200","author":"FDA Drug Approvals - nrd.2017.14.pdf"},{"key":"10.1016\/j.ejps.2018.04.016_bb0205","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1111\/j.2042-7158.2011.01301.x","article-title":"In-vitro permeability of poorly water soluble drugs in the phospholipid vesicle-based permeation assay: the influence of nonionic surfactants","volume":"63","author":"Fischer","year":"2011","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejps.2018.04.016_bb0210","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ijpharm.2011.10.026","article-title":"Application of simulated intestinal fluid on the phospholipid vesicle-based drug permeation assay","volume":"422","author":"Fischer","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2018.04.016_bb0220","series-title":"The Phospholipid Vesicle-Based Barrier: A Novel Method for Passive Drug Permeability Screening","author":"Flaten","year":"2007"},{"key":"10.1016\/j.ejps.2018.04.016_bb0225","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ejps.2006.03.008","article-title":"Drug permeability across a phospholipid vesicle-based barrier 2. Characterization of barrier structure, storage stability and stability towards pH changes","volume":"28","author":"Flaten","year":"2006","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2018.04.016_bb0230","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ejps.2005.08.007","article-title":"Drug permeability across a phospholipid vesicle based barrier: a novel approach for studying passive diffusion","volume":"27","author":"Flaten","year":"2006","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2018.04.016_bb0235","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ejps.2006.11.017","article-title":"Drug permeability across a phospholipid vesicle based barrier: 3. Characterization of drug-membrane interactions and the effect of agitation on the barrier integrity and on the permeability","volume":"30","author":"Flaten","year":"2007","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2018.04.016_bb0240","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ejps.2008.04.001","article-title":"Drug permeability across a phospholipid vesicle-based barrier 4. The effect of tensides, co-solvents and pH changes on barrier integrity and on drug permeability","volume":"34","author":"Flaten","year":"2008","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2018.04.016_bb0245","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ejps.2015.02.018","article-title":"In vitro skin models as a tool in optimization of drug formulation","volume":"75","author":"Flaten","year":"2015","journal-title":"Eur. J. Pharm. Sci."},{"issue":"Suppl. 1","key":"10.1016\/j.ejps.2018.04.016_bb0215","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1016\/S0169-409X(01)00184-3","article-title":"Transcytosis of nanoparticle and dendrimer delivery systems: evolving vistas","volume":"50","author":"Florence","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejps.2018.04.016_bb0250","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ejps.2016.09.018","article-title":"A novel microdialysis-dissolution\/permeation system for testing oral dosage forms: a proof-of-concept study","volume":"96","author":"Fong","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2018.04.016_bb0265","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1023\/A:1011910801212","article-title":"Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs","volume":"15","author":"Galia","year":"1998","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2018.04.016_bb0260","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jconrel.2013.12.009","article-title":"Characterization and evaluation of a modified PVPA barrier in comparison to Caco-2 cell monolayers for combined dissolution and permeation testing","volume":"175","author":"Gantzsch","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejps.2018.04.016_bb0275","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ejps.2008.08.004","article-title":"Comparison of drug transporter gene expression and functionality in Caco-2 cells from 10 different laboratories","volume":"35","author":"Hayeshi","year":"2008","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2018.04.016_bb0270","doi-asserted-by":"crossref","first-page":"681","DOI":"10.3109\/00365521.2014.898326","article-title":"Surface area of the digestive tract \u2013 revisited","volume":"49","author":"Helander","year":"2014","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.ejps.2018.04.016_bb0280","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ejps.2015.05.023","article-title":"Gastrointestinal behavior of nano- and microsized fenofibrate: in vivo evaluation in man and in vitro simulation by assessment of the permeation potential","volume":"77","author":"Hens","year":"2015","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2018.04.016_bb0285","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1002\/jps.24690","article-title":"Supersaturation and precipitation of posaconazole upon entry in the upper small intestine in humans","volume":"105","author":"Hens","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2018.04.016_bb0290","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1023\/A:1015848205447","article-title":"Characterization of the unstirred water layer in Caco-2 cell monolayers using a novel diffusion apparatus","volume":"8","author":"Hidalgo","year":"1991","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2018.04.016_bb0295","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ijpharm.2004.01.014","article-title":"Effect of simulated intestinal fluid on drug permeability estimation across Caco-2 monolayers","volume":"274","author":"Ingels","year":"2004","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2018.04.016_bb0300","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1021\/jm970530e","article-title":"Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes","volume":"41","author":"Kansy","year":"1998","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejps.2018.04.016_bb0305","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1111\/j.2042-7158.2010.01172.x","article-title":"In-vitro permeability screening of melt extrudate formulations containing poorly water-soluble drug compounds using the phospholipid vesicle-based barrier","volume":"62","author":"Kanzer","year":"2010","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejps.2018.04.016_bb0310","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ejpb.2006.08.010","article-title":"Absorption of poorly water soluble drugs subject to apical efflux using phospholipids as solubilizers in the Caco-2 cell model","volume":"66","author":"Kapitza","year":"2007","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2018.04.016_bb0315","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.ejps.2013.02.020","article-title":"Assessing vehicle effects on skin absorption using artificial membrane assays","volume":"50","author":"Karadzovska","year":"2013","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2018.04.016_bb0320","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1023\/A:1026107906191","article-title":"In vitro system to evaluate oral absorption of poorly water-soluble drugs: simultaneous analysis on dissolution and permeation of drugs","volume":"20","author":"Kataoka","year":"2003","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2018.04.016_bb0325","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S1773-2247(13)50092-X","article-title":"In vitro artificial membrane-natural mucosa correlation of carvedilol buccal delivery","volume":"23","author":"Khdair","year":"2013","journal-title":"J. Drug Delivery Sci. Technol."},{"key":"10.1016\/j.ejps.2018.04.016_bb0330","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.jpba.2017.07.022","article-title":"Surfactants enhance recovery of poorly soluble drugs during microdialysis sampling: implications for in vitro dissolution-\/permeation-studies","volume":"145","author":"Koplin","year":"2017","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ejps.2018.04.016_bb0335","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1021\/np300882f","article-title":"Applicability of a blood-brain barrier specific artificial membrane permeability assay at the early stage of natural product-based CNS drug discovery","volume":"76","author":"K\u00f6ncz\u00f6l","year":"2013","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.ejps.2018.04.016_bb0340","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.addr.2017.07.019","article-title":"The role of mucus in cell-based models used to screen mucosal drug delivery","volume":"124","author":"Lechanteur","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejps.2018.04.016_bb0345","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejpb.2016.12.027","article-title":"Quantitative analysis of lab-to-lab variability in Caco-2 permeability assays","volume":"114","author":"Lee","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2018.04.016_bb0350","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1021\/js970332a","article-title":"Human intestinal permeability","volume":"87","author":"Lennern\u00e4s","year":"1998","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2018.04.016_bb0375","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ejps.2008.03.001","article-title":"Passive oral drug absorption can be predicted more reliably by experimental than computational models\u2013fact or myth","volume":"34","author":"Linnankoski","year":"2008","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2018.04.016_bb0360","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1056-8719(00)00107-6","article-title":"Drug-like properties and the causes of poor solubility and poor permeability","volume":"44","author":"Lipinski","year":"2000","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.ejps.2018.04.016_bb0365","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejps.2018.04.016_bb0370","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1023\/B:PHAM.0000003380.44755.5a","article-title":"In vitro permeability of poorly aqueous soluble compounds using different solubilizers in the PAMPA assay with liquid chromatography\/mass spectrometry detection","volume":"20","author":"Liu","year":"2003","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2018.04.016_bb0380","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1111\/j.2042-7158.2010.01030.x","article-title":"Pharmaceutical applications of cyclodextrins: basic science and product development","volume":"62","author":"Loftsson","year":"2010","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejps.2018.04.016_bb0355","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/jps.2600620412","article-title":"Drug permeation through membranes. I. Effect of various substances on amobarbital permeation through polydimethylsiloxane","volume":"62","author":"Lovering","year":"1973","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2018.04.016_bb0385","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1080\/03639045.2017.1371730","article-title":"Development of phospholipid vesicle-based permeation assay models capable of evaluating percutaneous penetration enhancing effect","volume":"43","author":"Ma","year":"2017","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejps.2018.04.016_bb0390","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1021\/jm010152k","article-title":"Graphical model for estimating oral bioavailability of drugs in humans and other species from their Caco-2 permeability and in vitro liver enzyme metabolic stability rates","volume":"45","author":"Mandagere","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejps.2018.04.016_bb0395","doi-asserted-by":"crossref","first-page":"4192","DOI":"10.1021\/acs.molpharmaceut.7b00198","article-title":"Validation of dissolution testing with biorelevant media: an OrBiTo study","volume":"14","author":"Mann","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2018.04.016_bb0400","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1007\/s11095-013-1141-1","article-title":"In vitro and ex vivo investigation of the impact of luminal lipid phases on passive permeability of lipophilic small molecules using PAMPA","volume":"30","author":"Markopoulos","year":"2013","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2018.04.016_bb0405","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.tips.2015.02.009","article-title":"Quantifying the impact of transporters on cellular drug permeability","volume":"36","author":"Matsson","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejps.2018.04.016_bb0410","doi-asserted-by":"crossref","DOI":"10.1080\/21688370.2016.1176822","article-title":"Safety concerns over the use of intestinal permeation enhancers: a mini-review","volume":"4","author":"McCartney","year":"2016","journal-title":"Tissue Barriers"},{"key":"10.1016\/j.ejps.2018.04.016_bb0415","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.ejpb.2010.01.003","article-title":"Evaluation of various PAMPA models to identify the most discriminating method for the prediction of BBB permeability","volume":"74","author":"Mensch","year":"2010","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2018.04.016_bb0420","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1211\/jpp.57.12.0006","article-title":"Sulfasalazine transport in in-vitro, ex-vivo and in-vivo absorption models: contribution of efflux carriers and their modulation by co-administration of synthetic nature-identical fruit extracts","volume":"57","author":"Mols","year":"2005","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejps.2018.04.016_bb0425","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1002\/bdd.1803","article-title":"Mechanistic analysis of solute transport in an in vitro physiological two-phase dissolution apparatus","volume":"33","author":"Mudie","year":"2012","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.ejps.2018.04.016_bb0430","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ejps.2015.08.019","article-title":"Tuning the predictive capacity of the PAMPA-BBB model","volume":"79","author":"M\u00fcller","year":"2015","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2018.04.016_bb0435","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/jps.23845","article-title":"Improved permeability of acyclovir: optimization of mucoadhesive liposomes using the phospholipid vesicle-based permeation assay","volume":"103","author":"Naderkhani","year":"2014","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2018.04.016_bb0440","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1002\/jps.23954","article-title":"Development of a biomimetic phospholipid vesicle-based permeation assay for the estimation of intestinal drug permeability","volume":"103","author":"Naderkhani","year":"2014","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2018.04.016_bb0445","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ejps.2015.03.017","article-title":"Biomimetic PVPA in vitro model for estimation of the intestinal drug permeability using fasted and fed state simulated intestinal fluids","volume":"73","author":"Naderkhani","year":"2015","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2018.04.016_bb0450","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ejpb.2015.11.003","article-title":"Mucoadhesive vs. mucopenetrating particulate drug delivery","volume":"98","author":"Netsomboon","year":"2016","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2018.04.016_bb0455","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ejps.2005.02.009","article-title":"pH-Dependent passive and active transport of acidic drugs across Caco-2 cell monolayers","volume":"25","author":"Neuhoff","year":"2005","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2018.04.016_bb0465","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ejps.2004.02.003","article-title":"PAMPA\u2013a drug absorption in vitro model 8. Apparent filter porosity and the unstirred water layer","volume":"22","author":"Nielsen","year":"2004","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2018.04.016_bb0460","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1462-5822.2006.00694.x","article-title":"Dendritic cells in the recognition of intestinal microbiota","volume":"8","author":"Niess","year":"2006","journal-title":"Cell. Microbiol."},{"key":"10.1016\/j.ejps.2018.04.016_bb0470","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.xphs.2015.10.030","article-title":"The proteome of filter-grown Caco-2 cells with a focus on proteins involved in drug disposition","volume":"105","author":"\u00d6lander","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2018.04.016_bb0475","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1021\/jm060230+","article-title":"Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability","volume":"49","author":"Ottaviani","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejps.2018.04.016_bb0480","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3109\/08982104.2014.899368","article-title":"Liposomes for (trans)dermal drug delivery: the skin-PVPA as a novel in vitro stratum corneum model in formulation development","volume":"24","author":"Palac","year":"2014","journal-title":"J. Liposome Res."},{"key":"10.1016\/j.ejps.2018.04.016_bb0495","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1023\/A:1012188625088","article-title":"Polar molecular surface properties predict the intestinal absorption of drugs in humans","volume":"14","author":"Palm","year":"1997","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2018.04.016_bb0485","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/03639040500465991","article-title":"Use of simulated intestinal fluids with Caco-2 cells and rat ileum","volume":"32","author":"Patel","year":"2006","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejps.2018.04.016_bb0490","author":"Pion Inc"},{"key":"10.1016\/j.ejps.2018.04.016_bb0500","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.colsurfb.2009.06.033","article-title":"Alginate-magnesium aluminum silicate films for buccal delivery of nicotine","volume":"74","author":"Pongjanyakul","year":"2009","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.ejps.2018.04.016_bb0505","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/0304-4157(91)90016-P","article-title":"Structure-function relationships in intestinal brush border membranes","volume":"1071","author":"Proulx","year":"1991","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejps.2018.04.016_bb0510","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S1043-4526(08)60029-7","article-title":"Membrane vesicles","volume":"40","author":"Proulx","year":"1996","journal-title":"Adv. Food Nutr. Res."},{"key":"10.1016\/j.ejps.2018.04.016_bb0515","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1002\/jps.24603","article-title":"Characterization of human duodenal fluids in fasted and fed state conditions","volume":"105","author":"Riethorst","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2018.04.016_bb0520","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/j.1365-2125.1987.tb03108.x","article-title":"Intestinal metabolism of ethinyloestradiol and paracetamol in vitro: studies using Ussing chambers","volume":"23","author":"Rogers","year":"1987","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2018.04.016_bb0525","first-page":"G608","article-title":"Mechanisms maintaining a low-pH microclimate in the intestine","volume":"248","author":"Shiau","year":"1985","journal-title":"Am. J. Phys."},{"key":"10.1016\/j.ejps.2018.04.016_bb0540","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1002\/cbdv.200900149","article-title":"A PAMPA study of the permeability-enhancing effect of new ceramide analogues","volume":"6","author":"Sink\u00f3","year":"2009","journal-title":"Chem. Biodivers."},{"key":"10.1016\/j.ejps.2018.04.016_bb0545","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.ejps.2012.01.011","article-title":"Skin-PAMPA: a new method for fast prediction of skin penetration","volume":"45","author":"Sink\u00f3","year":"2012","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2018.04.016_bb0530","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ijpharm.2017.03.002","article-title":"Evaluation of a dynamic dissolution\/permeation model: mutual influence of dissolution and barrier-flux under non-steady state conditions","volume":"522","author":"Sironi","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2018.04.016_bb0535","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ejps.2016.09.001","article-title":"Dynamic dissolution-\/permeation-testing of nano- and microparticle formulations of fenofibrate","volume":"96","author":"Sironi","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2018.04.016_bb0550","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.ijpharm.2014.11.035","article-title":"In situ perfusion in rodents to explore intestinal drug absorption: challenges and opportunities","volume":"478","author":"Stappaerts","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2018.04.016_bb0555","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ejps.2017.12.014","article-title":"The effect of 2-hydroxypropyl-\u03b2-cyclodextrin on the intestinal permeation through mucus","volume":"114","author":"Stappaerts","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2018.04.016_bb0560","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0378-5173(01)00845-6","article-title":"Optimized conditions of bio-mimetic artificial membrane permeation assay","volume":"228","author":"Sugano","year":"2001","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2018.04.016_bb0565","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0378-5173(02)00240-5","article-title":"Prediction of passive intestinal absorption using bio-mimetic artificial membrane permeation assay and the paracellular pathway model","volume":"241","author":"Sugano","year":"2002","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2018.04.016_bb0570","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1023\/A:1020483911355","article-title":"Comparison of human duodenum and Caco-2 gene expression profiles for 12,000 gene sequences tags and correlation with permeability of 26 drugs","volume":"19","author":"Sun","year":"2002","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2018.04.016_bb0575","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1023\/A:1016086003070","article-title":"Carrier-mediated intestinal transport of drugs","volume":"13","author":"Tsuji","year":"1996","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2018.04.016_bb0580","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1021\/js970218s","article-title":"Membrane transport of drugs in different regions of the intestinal tract of the rat","volume":"87","author":"Ungell","year":"1998","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2018.04.016_bb0585","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1021\/jm020017n","article-title":"Molecular properties that influence the oral bioavailability of drug candidates","volume":"45","author":"Veber","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejps.2018.04.016_bb0590","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1039\/C6MD00545D","article-title":"Towards the rational design of novel drugs based on solubility, partitioning\/distribution, biomimetic permeability and biological activity exemplified by 1,2,4-thiadiazole derivatives","volume":"8","author":"Volkova","year":"2017","journal-title":"Med. Chem. Commun."},{"key":"10.1016\/j.ejps.2018.04.016_bb0595","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ejpb.2012.05.008","article-title":"Predicting the oral absorption of a poorly soluble, poorly permeable weak base using biorelevant dissolution and transfer model tests coupled with a physiologically based pharmacokinetic model","volume":"82","author":"Wagner","year":"2012","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2018.04.016_bb0600","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1021\/jm001020e","article-title":"High-throughput permeability pH profile and high-throughput alkane\/water log P with artificial membranes","volume":"44","author":"Wohnsland","year":"2001","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejps.2018.04.016_bb0605","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ejps.2014.11.010","article-title":"Evaluation of fasted state human intestinal fluid as apical solvent system in the Caco-2 absorption model and comparison with FaSSIF","volume":"67","author":"Wuyts","year":"2015","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2018.04.016_bb0610","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.ijpharm.2014.12.021","article-title":"Evaluation of fasted and fed state simulated and human intestinal fluids as solvent system in the Ussing chambers model to explore food effects on intestinal permeability","volume":"478","author":"Wuyts","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2018.04.016_bb0615","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1080\/08982104.2016.1231205","article-title":"Characterization of a liposome-based artificial skin membrane for in vitro permeation studies using Franz diffusion cell device","volume":"27","author":"Zhang","year":"2017","journal-title":"J. Liposome Res."},{"key":"10.1016\/j.ejps.2018.04.016_bb0620","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S0223-5234(02)01360-0","article-title":"A comparative study of artificial membrane permeability assay for high throughput profiling of drug absorption potential","volume":"37","author":"Zhu","year":"2002","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejps.2018.04.016_bb0625","series-title":"Developing Solid Oral Dosage Forms","first-page":"297","article-title":"Chapter 11 - oral absorption basics: pathways and physicochemical and biological factors affecting absorption","author":"Zhu","year":"2017"},{"key":"10.1016\/j.ejps.2018.04.016_bb0630","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.bbamem.2007.03.026","article-title":"Use of cyclodextrins to manipulate plasma membrane cholesterol content: evidence, misconceptions and control strategies","volume":"1768","author":"Zidovetzki","year":"2007","journal-title":"Biochim. Biophys. Acta"}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098718301751?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098718301751?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,22]],"date-time":"2018-08-22T13:24:48Z","timestamp":1534944288000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098718301751"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":126,"alternative-id":["S0928098718301751"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2018.04.016","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug permeability profiling using cell-free permeation tools: Overview and applications","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2018.04.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}